Falsely elevated digoxin levels with the chemiluminescent microparticle immunoassay test method in patients receiving enzalutamide treatment

doi:10.19803/j.1672-8629.20269910

Chinese Journal of Pharmacovigilance ›› 2026, Vol. 23 ›› Issue (10): 1188-1188.
DOI: 10.19803/j.1672-8629.20269910

Previous Articles Next Articles

Falsely elevated digoxin levels with the chemiluminescent microparticle immunoassay test method in patients receiving enzalutamide treatment

Falsely elevated digoxin levels with the chemiluminescent microparticle immunoassay test method in patients receiving enzalutamide treatment

Online:2026-10-15 Published:2026-10-16

Abstract

CLC Number:

R979.1
R994.11

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20269910

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I10/1188

[1]	Zhi Yating, Yang Bo, Wang Haojie, Mu Taiyang, Feng Yulong, Hu Kaiyong, Zhang Min, Huang Qian, Yang Huaqian. Schisandrin B attenuates cardiotoxicity induced by cyclophosphamide and epirubicin [J]. Chinese Journal of Pharmacovigilance, 2026, 23(10): 1131-1138.
[2]	Wang Zebin, Jiang Zhiwei, Gong Guanwen. One case of fulminant type 1 diabetes mellitus complicated with diabetic ketoacidosis and hyperosmolar hyperglycemic state caused by nivolumab [J]. Chinese Journal of Pharmacovigilance, 2026, 23(10): 1185-1187.
[3]	Wu Qian, Qin Yong, Wang Lushan, Han Zhongyu. One case of myocarditis caused by gefitinib tablets [J]. Chinese Journal of Pharmacovigilance, 2026, 23(9): 1053-1055.
[4]	Lyu Xinge, Liu Aijia, Wu Yi, Pan Chen, Wang Yuting, Cui Xiangli. Multicenter case analysis of thyroid dysfunction associated with immune checkpoint inhibitors [J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 892-897.
[5]	Li Jianping, Du Ning, Tang Min, Zhou Ziyuan, Zuo Jing. 691 cases of adverse drug reactions caused by new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 904-908.
[6]	Gao Chaozheng, Zhao Yifan, Su Li, Li Ping. Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients [J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 934-937.
[7]	Xie Huali, Guan Bixi, Zhuo Yubo, He Jieli, Chen Zhe. One case of sequential delayed-to-immediate hypersensitivity reaction caused by sacituzumab tirumotecan for injection [J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 938-940.
[8]	GAO Zhichao, ZHAO Chenguang, FAN Youning, XUE Wenhan, LIANG Jingwei, WANG Lin, MENG Fanhao. Molecular Mechanisms of Mitochondrial Dynamics and Endoplasmic Reticulum Stress in Tumor Chemoresistance [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 601-606.
[9]	WANG Yuting, LYU Xinge, PAN Chen, WU Yi, CUI Xiangli. Reports of Adverse Reactions of Immune Checkpoint Inhibitor-Related Colitis [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 681-685.
[10]	LAN Zhihui, BU Lijia, NING Jie, JIANG Jiemei, YANG Yanbiao. One Case of Autoimmune Hemolytic Anemia Caused by Camrelizumab for Injection [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 696-698.
[11]	. FDA is Requiring Warning about Vitamin B₆ Deficiency and Associated Seizures for Drug Products Containing Carbidopa/Levodopa [J]. Chinese Journal of Pharmacovigilance, 2026, 23(6): 720-720.
[12]	SI Liuzhe, DENG Rui, LIU Qi, YUAN Mingliang, QU Bing, ZHANG Ailing, HAN Xue, CHAI Yuna. One Case of Lower Gastrointestinal Bleeding Caused by Sunitinib Malate Capsules [J]. Chinese Journal of Pharmacovigilance, 2026, 23(4): 473-475.
[13]	JIANG Yanlin, DENG Jungang, CHEN Wei, ZHANG Jingjing, FANG Chunxia, QIN Zhongyu, PENG Yingzhi, GUO Bing, LIAO Rujia. Serious Adverse Reactions and Risks Caused by Camrelizumab for Injection [J]. Chinese Journal of Pharmacovigilance, 2026, 23(3): 307-311.
[14]	WANG Yuting, ZHU Fangyi, LYU Xinge, PAN Chen, WU Yi, CUI Xiangli. Cases of Colitis Caused by Immune Checkpoint Inhibitors [J]. Chinese Journal of Pharmacovigilance, 2026, 23(3): 318-322.
[15]	JI Liu, HAO Min, WU Wenhui. One Case of EDTA-Dependent Pseudothrombocytopenia Induced by Paclitaxel Liposome for Injection [J]. Chinese Journal of Pharmacovigilance, 2026, 23(3): 334-336.

Falsely elevated digoxin levels with the chemiluminescent microparticle immunoassay test method in patients receiving enzalutamide treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics